Organized colorectal cancer screening program started in Germany

09

May 2019

Up to now, only the breast cancer screening program was an organized screening program (the national invitation program targets all relevant candidates on the national level). The cervical and colorectal screening program were in the national roll-out phase (soon-to-become-organized on the national level). Other screening programs are of opportunistic nature in Germany.

However, on April 4, 2019, it has been announced that the colorectal screening program has become organized on the national level. According to the organized screening program, starting on 19th of April, men of at least 50 years of age and women of at least 55 years of age are required to undergo a colonoscopy because of the increase of colorectal cancer risk. The candidates will receive the invitation. A new check-up can be carried out after 9 calendar years.

In addition, the Evaluation Committee has now agreed on a higher compensation for the more detailed consultation. For this purpose, the fee order position 01740 was changed and the score increased from €103 to €115 (€12.45 euros). Beginning from 19th of April, this option will also be available for all insured men aged 50 and over. Until now, the detailed consultation was only available for men of at least 55 years of age.

The regulations for the immunological testing for fecal occult blood (iFOBT) remain unchanged: a fecal occult blood test can be carried out annually in both men and women aged over 50 years, and bi-annually beginning from 55 years of age.

The Federal Joint Committee (G-BA) adopted last year the directive on organized cancer screening programs (oKFE-RL). Colorectal cancer screening is the first organized program to be implemented thereafter. Insured people of at least 50 years of age will be regularly invited for screening by the health insurance companies beginning from July 2019.

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more

07

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Read more